TROP-2 was previously classified as an oncogene and high TROP-2 expression levels were linked to poor prognosis across various tumor entities including breast cancer (Lin et al. 2014), prostate cancer (Trerotola et al. 2013), and colon cancer (Zhao et al. 2015). Here, TACSTD2 is linked to prostate cancer.